Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. [electronic resource]
Producer: 20090414Description: 1686-97 p. digitalISSN:- 1078-0432
- Adolescent
- Adult
- Aged
- Animals
- Antineoplastic Agents, Alkylating -- therapeutic use
- Apoptosis -- drug effects
- Benzamides
- Blotting, Western
- Cell Cycle -- drug effects
- Cell Proliferation -- drug effects
- Diterpenes -- therapeutic use
- Drug Resistance, Neoplasm
- Epoxy Compounds -- therapeutic use
- Female
- Flow Cytometry
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Immunoenzyme Techniques
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Membrane Potential, Mitochondrial -- drug effects
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Middle Aged
- Mutation -- genetics
- Myeloid Cell Leukemia Sequence 1 Protein
- Phenanthrenes -- therapeutic use
- Piperazines -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-akt -- genetics
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Pyrimidines -- therapeutic use
- RNA, Messenger -- genetics
- Reactive Oxygen Species -- metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction -- drug effects
- Transcription, Genetic -- drug effects
- Tripterygium -- chemistry
- Tumor Cells, Cultured
- Tumor Stem Cell Assay
- Xenograft Model Antitumor Assays
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.